Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a parenteral formulation for intracisternal or intravenous use. It is used to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients. GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimotop acts on cerebral vasculature to reduce the risk of vasospasm after hemorrhagic events.

- Subarachnoid hemorrhage: prevention of cerebral vasospasm following the bleed. - Cerebral vasospasm: reduction of vasospasm severity and improvement of neurological outcomes. - Neuroprotection: supports neuronal survival by enhancing cerebral blood flow after hemorrhage.

Nimotop may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Hypotension: lowered blood pressure, especially when given rapidly. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: warmth and redness of the skin. - Dizziness or vertigo: sensation of spinning. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may lead to syncope. - Myocardial infarction: rare cardiac ischemic events. - Allergic reaction: rash, pruritus, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Neutropenia: reduced white blood cell count. - Seizures: uncommon neurologic events.

Before initiating Nimotop, clinicians should assess patient‑specific factors and monitor for safety.

- Blood pressure monitoring: check for hypotension before and during therapy. - Hepatic function: evaluate liver enzymes prior to use. - Severe hypotension: avoid in patients with already low blood pressure. - Concomitant vasodilators: use caution when combined with other agents that lower vascular tone. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nimotop can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nimodipine plasma levels. - Nitrates: risk of profound hypotension. - Other potent vasodilators: synergistic blood pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Diuretics: enhance hypotensive response. - Antihypertensive agents: require blood pressure monitoring. - Antiplatelet or anticoagulant drugs: monitor for bleeding risk.